조직병리학 시장 : 전략적 인사이트와 예측(2026-2031년)

The Histopathology Market is set to reach USD 21.54 billion in 2031, growing at a CAGR of 8.6 % from USD 10.27 billion in 2026.

The histopathology market is undergoing significant transformation driven by the paradigm shift toward precision medicine, digital pathology, and laboratory automation. The market's evolution is characterized by the growing recognition that histopathological examination remains the diagnostic gold standard for confirming malignancies and determining treatment strategies, while simultaneously evolving into a digitally connected discipline that supports biomarker-driven therapy selection. The convergence of automated tissue processing systems, whole-slide imaging, artificial intelligence-assisted image analysis, and cloud-based pathology platforms is enabling more efficient, standardized, and accurate diagnostic workflows. Healthcare systems are expanding pathology capacity to accommodate rising diagnostic demand from increasing cancer incidence and expanding screening programs, encouraging investments in automated instruments, advanced staining technologies, and digital pathology solutions. The increasing global burden of cancer remains the primary factor driving market expansion, with tissue analysis confirming disease type, stage, and biological characteristics essential for personalized treatment planning. Pharmaceutical companies continue increasing investments in translational research, supporting greater demand for histopathology services throughout drug discovery, preclinical safety studies, and clinical development. The market is witnessing significant investment in companion diagnostics, multiplex immunohistochemistry, and spatial biology technologies, positioning histopathology as a central component of precision oncology across global healthcare systems.

Market Drivers

The rising global cancer burden represents the primary driver for the histopathology market. Cancer diagnosis depends heavily on histopathological examination because tissue analysis confirms disease type, stage, and biological characteristics. Growing cancer incidence continues increasing biopsy volumes across hospitals and diagnostic laboratories. Healthcare providers are expanding pathology capacity to accommodate rising diagnostic demand, encouraging investments in automated instruments, advanced staining technologies, and digital pathology platforms that improve diagnostic accuracy and laboratory efficiency, resulting in sustained growth in histopathology utilization. Digital pathology adoption is further accelerating market growth by enabling faster diagnosis and remote consultation. Healthcare organizations increasingly implement digital pathology to improve diagnostic workflows and specialist collaboration. Whole-slide imaging systems, artificial intelligence-enabled software, and cloud-based image management platforms reduce reporting turnaround time while supporting remote consultations. Vendors continue enhancing integrated digital ecosystems, accelerating technology adoption throughout developed and emerging healthcare markets. Automation is improving laboratory productivity and workflow standardization. Pathology laboratories require greater operational efficiency because specimen volumes continue increasing while workforce shortages remain significant. Automated tissue processors, slide stainers, embedding systems, and microtomes reduce manual intervention and improve workflow standardization. Healthcare providers continue replacing legacy equipment with automated solutions that enhance productivity, minimize errors, and support consistent diagnostic quality. Precision medicine is expanding advanced histopathology applications through biomarker-driven therapy selection. Precision oncology increasingly relies on detailed tissue characterization to guide targeted therapies and companion diagnostic testing. Pharmaceutical companies and healthcare providers continue expanding biomarker-driven treatment strategies, increasing demand for immunohistochemistry, digital pathology, and molecular pathology technologies.

Market Restraints

High capital investment requirements for automated histopathology instruments and digital pathology infrastructure limit adoption among smaller laboratories. The substantial upfront costs for equipment and digital systems create barriers for facilities with constrained budgets. Regulatory compliance, quality assurance requirements, and laboratory accreditation standards increase implementation complexity for new technologies. The rigorous validation and documentation requirements create challenges for laboratories adopting innovative solutions. Limited availability of experienced pathologists and laboratory professionals constrains efficient utilization of advanced diagnostic platforms. The shortage of specialized personnel limits the scalability of digital pathology and AI-assisted diagnostics. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new histopathology solutions. The evolving regulatory landscape requires continuous adaptation, increasing operational costs and time-to-market for new products.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of integrated digital pathology workflows. Conventional tissue preparation technologies continue to support routine diagnostic workflows, while laboratories increasingly invest in automation to reduce manual intervention and improve reproducibility. Digital pathology and whole-slide imaging are experiencing the fastest adoption because healthcare providers are implementing remote diagnostics, artificial intelligence-assisted pathology, and centralized reporting platforms. Tissue processing systems, microtomes, cryostats, and embedding systems form the foundation of histopathology workflow automation. Slide staining systems, including advanced immunohistochemistry platforms, support biomarker testing for precision oncology. The segment analysis reveals that consumables and reagents generate the largest recurring revenue because every tissue sample requires stains, antibodies, cassettes, slides, embedding media, and processing chemicals, making this the most consistent demand segment. Instruments account for substantial capital investments as laboratories require automated tissue processors, microtomes, slide stainers, and digital scanners to improve throughput and diagnostic consistency. Software is expanding rapidly as pathology laboratories adopt digital pathology, AI-assisted image analysis, workflow management, and laboratory information system integration. Disease diagnosis represents the largest application segment because histopathology remains the gold standard for confirming cancer and numerous non-oncological diseases through tissue examination. Drug discovery and development continues expanding as pharmaceutical and biotechnology companies increasingly depend on histopathological evaluation for preclinical safety studies, biomarker validation, and therapeutic development. Hospitals and diagnostic laboratories represent key end-user segments, with academic and research institutes playing an increasingly important role in translational research. The integration of artificial intelligence is becoming increasingly important because AI continues improving image interpretation, workflow prioritization, and quantitative tissue analysis. Healthcare providers increasingly integrate AI into digital pathology platforms to improve diagnostic consistency while supporting precision medicine initiatives.

Competitive and Strategic Outlook

The competitive landscape features established histopathology and life science companies alongside specialized digital pathology and diagnostic providers. F. Hoffmann-La Roche maintains one of the strongest competitive positions by integrating tissue diagnostics, companion diagnostics, digital pathology, and precision oncology into a unified ecosystem, with its VENTANA platform and advanced immunohistochemistry assays supporting hospitals and pharmaceutical companies. Danaher operates through Leica Biosystems, one of the world's leading providers of histopathology solutions, offering comprehensive tissue processing systems, microtomes, slide stainers, digital pathology platforms, and whole-slide imaging technologies. Thermo Fisher Scientific competes through its broad pathology consumables, antibodies, tissue diagnostics, and laboratory workflow portfolio, continuing to integrate histopathology with molecular diagnostics and precision medicine applications. Agilent Technologies strengthens its market position through Dako-branded immunohistochemistry systems, companion diagnostics, and automated staining platforms, focusing on biomarker testing that supports targeted oncology therapies. PHC Holdings, through Epredia, provides tissue processing systems, slide preparation equipment, cryostats, microtomes, and pathology workflow solutions. Sakura Finetek specializes exclusively in histopathology workflow automation, developing tissue processors, embedding systems, slide stainers, and digital pathology technologies. Abbott supports histopathology through biomarker development, companion diagnostics, and precision medicine initiatives. Merck KGaA supports the histopathology market primarily through research reagents, antibodies, laboratory chemicals, and biomarker collaborations. Companies are pursuing product portfolio expansion through innovation in digital pathology platforms, AI-enabled image analysis, and companion diagnostic technologies. Recent key developments include Roche receiving FDA clearance for the VENTANA TROP2 RxDx Device, expanding its companion diagnostics portfolio. Danaher (Leica Biosystems) showcased new digital pathology and AI-enabled workflow solutions at USCAP 2025. Thermo Fisher Scientific introduced additional digital pathology workflow solutions and expanded its pathology reagent portfolio. Agilent Technologies expanded its pathology diagnostics portfolio by strengthening companion diagnostic collaborations. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing emerging markets where healthcare infrastructure is expanding. Mergers and acquisitions are occurring as larger players seek to expand market presence and technology capabilities.

Short Conclusion

The histopathology market is positioned for sustained growth driven by the convergence of rising cancer burden, digital pathology adoption, and precision medicine expansion. The transition from conventional microscopy toward digitally connected, AI-enabled diagnostic workflows represents a fundamental shift in tissue-based diagnostics. While challenges related to capital investment, regulatory compliance, and workforce shortages persist, strategic investments in technology, automation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with histopathology evolving from a routine diagnostic discipline into a central component of precision medicine, supporting companion diagnostics, translational research, and personalized healthcare across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Histopathology Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Disease Burden and Biopsy Volume Analysis
• 3.8 Histopathology Testing Volume Analysis
• 3.9 Laboratory Workflow Analysis
• 3.10 Role of Histopathology in Disease Diagnosis and Precision Medicine

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Product Innovation
• 6.3 Digital Pathology Integration
• 6.4 Artificial Intelligence in Histopathology
• 6.5 Whole Slide Imaging and Image Analysis
• 6.6 Automation in Histopathology Laboratories
• 6.7 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Histopathology Market Landscape Analysis

• 8.1 Analysis by Product Type
  • 8.1.1 Instruments
  • 8.1.2 Consumables & Reagents
  • 8.1.3 Software
• 8.2 Analysis by Technology Platform
  • 8.2.1 Tissue Processing
  • 8.2.2 Tissue Embedding
  • 8.2.3 Microtomy
  • 8.2.4 Tissue Staining
  • 8.2.5 Digital Pathology
  • 8.2.6 Whole Slide Imaging
• 8.3 Analysis by Specimen Type
  • 8.3.1 Breast Tissue
  • 8.3.2 Gastrointestinal Tissue
  • 8.3.3 Skin Tissue
  • 8.3.4 Lung Tissue
  • 8.3.5 Prostate Tissue
  • 8.3.6 Other Tissue Types
• 8.4 Analysis by Clinical Application
  • 8.4.1 Oncology
  • 8.4.2 Infectious Diseases
  • 8.4.3 Neurological Disorders
  • 8.4.4 Renal Diseases
  • 8.4.5 Other Diseases

9. Global Histopathology Market Segment Analysis (2021-2035)

• 9.1 By Product
  • 9.1.1 Instruments
  • 9.1.2 Consumables & Reagents
  • 9.1.3 Software
• 9.2 By Technology
  • 9.2.1 Tissue Processing Systems
  • 9.2.2 Microtomes
  • 9.2.3 Cryostats
  • 9.2.4 Tissue Embedding Systems
  • 9.2.5 Slide Staining Systems
  • 9.2.6 Digital Pathology Systems
  • 9.2.7 Whole Slide Imaging Systems
• 9.3 By Application
  • 9.3.1 Disease Diagnosis
  • 9.3.2 Drug Discovery & Development
  • 9.3.3 Academic Research
• 9.4 By End User
  • 9.4.1 Hospitals
  • 9.4.2 Diagnostic Laboratories
  • 9.4.3 Academic & Research Institutes
  • 9.4.4 Pharmaceutical & Biotechnology Companies
  • 9.4.5 Contract Research Organizations

10. Global Histopathology Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Histopathology Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 Japan
• 11.10 China
• 11.11 India
• 11.12 South Korea
• 11.13 Australia
• 11.14 Brazil
• 11.15 Mexico
• 11.16 Saudi Arabia
• 11.17 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Danaher Corporation
  • 13.2.1 Company Overview
  • 13.2.2 Financials
  • 13.2.3 Product Portfolio
  • 13.2.4 Recent Developments
• 13.3 Thermo Fisher Scientific Inc.
  • 13.3.1 Company Overview
  • 13.3.2 Financials
  • 13.3.3 Product Portfolio
  • 13.3.4 Recent Developments
• 13.4 Agilent Technologies, Inc.
  • 13.4.1 Company Overview
  • 13.4.2 Financials
  • 13.4.3 Product Portfolio
  • 13.4.4 Recent Developments
• 13.5 PHC Holdings Corporation
  • 13.5.1 Company Overview
  • 13.5.2 Financials
  • 13.5.3 Product Portfolio
  • 13.5.4 Recent Developments
• 13.6 Sakura Finetek Japan Co., Ltd.
  • 13.6.1 Company Overview
  • 13.6.2 Financials
  • 13.6.3 Product Portfolio
  • 13.6.4 Recent Developments
• 13.7 Abbott Laboratories
  • 13.7.1 Company Overview
  • 13.7.2 Financials
  • 13.7.3 Product Portfolio
  • 13.7.4 Recent Developments
• 13.8 Merck KGaA
  • 13.8.1 Company Overview
  • 13.8.2 Financials
  • 13.8.3 Product Portfolio
  • 13.8.4 Recent Developments
• 13.9 Bio SB Inc.
  • 13.9.1 Company Overview
  • 13.9.2 Financials
  • 13.9.3 Product Portfolio
  • 13.9.4 Recent Developments
• 13.10 Biocare Medical, LLC
  • 13.10.1 Company Overview
  • 13.10.2 Financials
  • 13.10.3 Product Portfolio
  • 13.10.4 Recent Developments
• 13.11 StatLab Medical Products
  • 13.11.1 Company Overview
  • 13.11.2 Financials
  • 13.11.3 Product Portfolio
  • 13.11.4 Recent Developments
• 13.12 Histo-Line Laboratories S.r.l.
  • 13.12.1 Company Overview
  • 13.12.2 Financials
  • 13.12.3 Product Portfolio
  • 13.12.4 Recent Developments
• 13.13 General Data Healthcare, Inc.
  • 13.13.1 Company Overview
  • 13.13.2 Financials
  • 13.13.3 Product Portfolio
  • 13.13.4 Recent Developments
• 13.14 CellPath Ltd.
  • 13.14.1 Company Overview
  • 13.14.2 Financials
  • 13.14.3 Product Portfolio
  • 13.14.4 Recent Developments
• 13.15 SLEE medical GmbH
  • 13.15.1 Company Overview
  • 13.15.2 Financials
  • 13.15.3 Product Portfolio
  • 13.15.4 Recent Developments

14. Global Histopathology Market Commercial Forecast Analysis

• 14.1 Tissue Processing Systems
• 14.2 Tissue Embedding Systems
• 14.3 Microtomes
• 14.4 Cryostats
• 14.5 Slide Staining Systems
• 14.6 Digital Pathology Systems
• 14.7 Whole Slide Imaging Systems
• 14.8 Histopathology Reagents & Consumables

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends